Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OVRAL-28 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: suppresses gonadotropin release via estrogen and progestin, inhibiting ovulation, thickening cervical mucus, and altering endometrial lining.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females aged ≥15 years who have no known contraindications and have achieved menarche
Prevention of pregnancy (FDA-approved)
One tablet (norgestrel 0.3 mg, ethinyl estradiol 0.03 mg) orally once daily for 21 consecutive days, followed by 7 days of placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Ethinyl estradiol: terminal half-life 13-27 hours (mean ~17 hours); norgestrel: terminal half-life 11-45 hours (mean ~24 hours). Clinical context: steady-state reached within 5-7 days; accumulation minimal with daily dosing.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily hepatic via CYP3A4, undergoes first-pass metabolism; norgestrel: hepatic reduction and conjugation, partially via CYP3A4.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~40% as metabolites; fecal: ~60% via biliary excretion, primarily as glucuronide and sulfate conjugates.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Ethinyl estradiol: 97-98% bound, primarily to albumin; norgestrel: 93-95% bound, primarily to sex hormone-binding globulin (SHBG) and albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Ethinyl estradiol: 2.5-4.0 L/kg; norgestrel: 2.0-3.5 L/kg. High Vd indicates extensive tissue distribution and binding.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: ethinyl estradiol ~40-50% (due to first-pass metabolism); norgestrel ~60-70% (variable due to presystemic metabolism).
Oral: ~70% due to first-pass metabolism.
No dosage adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min); use with caution due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute hepatitis, hepatic adenomas, or severe cirrhosis (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), consider alternative therapy; if used, monitor liver function closely and reduce dose if tolerated.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (one tablet daily).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause. No specific dosing adjustments provided for elderly patients; consider increased risk of thromboembolic events and cardiovascular disease.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events. Combination oral contraceptives are contraindicated in women over 35 who smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thrombotic disorders (venous thromboembolism, stroke, MI),Elevated blood pressure,Gallbladder disease,Hepatic neoplasia,Glucose intolerance,Retinal thrombosis,Depression
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Current or history of thrombotic disorders,Known or suspected breast carcinoma,Undiagnosed abnormal genital bleeding,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions known; however, grapefruit juice may increase ethinyl estradiol exposure. High-fat meals may slightly reduce absorption but not clinically significant. Advise consistent intake with food to minimize gastrointestinal upset.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy category X. First trimester: risk of congenital malformations (neural tube defects, cardiovascular anomalies) and spontaneous abortion. Second and third trimesters: associated with fetal adrenal suppression, hepatic impairment, and potential for masculinization of female genitalia.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Contraindicated during breastfeeding. Estrogens and progestins are excreted in human milk in low concentrations (M/P ratio not established). Potential for adverse effects on the infant including jaundice and breast enlargement.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately upon pregnancy confirmation.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Ovral-28 is a combination oral contraceptive containing norgestrel and ethinyl estradiol. It is dosed as 28-day regimen with 21 active pills and 7 placebo. Patients should be counseled about the risk of thromboembolism, especially if over 35 years old and smoking. Efficacy may be reduced with concurrent use of certain anticonvulsants (e.g., phenytoin, carbamazepine) and antibiotics (e.g., rifampin). Instruct patients to take at the same time daily to maintain consistent serum levels. Missed doses require backup contraception; refer to package insert for missed pill algorithm.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time, preferably with a meal to reduce nausea.,Do not skip pills; if a pill is missed, follow the instructions in the patient information leaflet and use backup contraception as directed.,Smoking increases the risk of serious cardiovascular side effects, especially in women over 35. Avoid smoking while on this medication.,Use backup contraception (like condoms) when starting the pill and if you miss pills or take certain other medications.,Common side effects include nausea, headache, breast tenderness, and breakthrough bleeding, which often improve after 2-3 months.,Seek medical attention immediately if you experience symptoms of blood clots: sudden chest pain, shortness of breath, leg pain/swelling, or sudden severe headache.,This medication does not protect against HIV or other sexually transmitted infections.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OVRAL-28 vs AFIRMELLE, answered by our medical review team.
OVRAL-28 is a Oral Contraceptive that works by Combination oral contraceptive: suppresses gonadotropin release via estrogen and progestin, inhibiting ovulation, thickening cervical mucus, and altering endometrial lining.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OVRAL-28 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OVRAL-28 is: One tablet (norgestrel 0.3 mg, ethinyl estradiol 0.03 mg) orally once daily for 21 consecutive days, followed by 7 days of placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OVRAL-28 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OVRAL-28 is classified as Category C. Pregnancy category X. First trimester: risk of congenital malformations (neural tube defects, cardiovascular anomalies) and spontaneous abortion. Second and third trimesters: assoc. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.